C
FATE icon

Covestor’s Fate Therapeutics FATE Stock Holding History

Covestor’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31
Closed – – 2369
2025
Q1 		$0 Hold
31
– – ﹤0.01% 2381
2024
Q4 		$0 Buy
31
+18
+138% +$45 ﹤0.01% 2391
2024
Q3 		$0 Sell
13
-1
-7% -$4 ﹤0.01% 2375
2024
Q2 		$0 Hold
14
– – ﹤0.01% 2390
2024
Q1 		$0 Sell
14
-29
-67% -$180 ﹤0.01% 2386
2023
Q4 		$0 Buy
43
+24
+126% +$57 ﹤0.01% 2297
2023
Q3 		$0 Sell
19
-2
-10% -$7 ﹤0.01% 2276
2023
Q2 		$0 Sell
21
-1
-5% -$6 ﹤0.01% 2282
2023
Q1 		$0 Buy
22
+14
+175% +$84 ﹤0.01% 2184
2022
Q4 		$0 Sell
8
-1
-11% -$19 ﹤0.01% 2211
2022
Q3 		$0 Sell
9
-1
-10% -$29 ﹤0.01% 2168
2022
Q2 		$0 Sell
10
-225
-96% -$6.21K ﹤0.01% 2058
2022
Q1 		$9K Buy
235
+156
+197% +$6.04K 0.01% 1345
2021
Q4 		$5K Buy
+79
New +$4.48K 0.01% 1298

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Covestor's FATE Position: Q2 2025 in Review

Covestor sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 31 shares.

Covestor first reported a position in FATE in Q4 2021 and held it in 14 quarters. The position peaked at $9K in Q1 2022. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Covestor reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Covestor sold 31 Fate Therapeutics shares in Q2 2025.
  • Covestor first reported a position in Fate Therapeutics in Q4 2021 and held it in 14 quarters.
  • Covestor's Fate Therapeutics position peaked at $9K in Q1 2022.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Covestor's 13F filing for Q2 2025, filed 11 Aug 2025.